Wyeth 'no miracle drug' for Pfizer
Pfizer's $68bn takeover of Wyeth will give it a short-term boost, but won't solve Pfizer's biggest problem - lack of revenue.
"Pfizer knows a thing or two" about treating ailments, said Rob Cox on Breakingviews. And its $68bn takeover of Wyeth (NYSE:WYE), making it the world's number-one drug-maker by sales, "looks like decent therapy". Pfizer (NYSE:PFE) gets a short-term fix, adding consumer products, biotech and vaccines to its pipeline. It should give earnings an immediate boost and there are $3bn of costs to be taken out, said Alex Brummer in the Daily Mail. Pfizer is expected to fire 15% of the combined workforce around 19,000 employees and close five factories.
Many question how the $75bn firm would find new drugs and vaccines to generate growth, said Jonathan Rockoff in The Wall Street Journal. This isn't a case of "two drowning men grabbing on to each other," said Lex in the FT. "But Wyeth is no miracle drug." Pfizer chief Jeff Kindler has acknowledged he is eyeing up other potential takeover targets, with analysts suspecting biotech group Amgen tops the list. Faced with the threat of generic drugs and recession, other drug groups will also prop each other up. "This looks like a taste of deals to come," said Cox.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Investors pull money from UK equities as government warns of “painful” Budget
The government’s post-election honeymoon period has been short-lived, and investors are shying away from UK equities as a result
By Katie Williams Published
-
Top global fintech companies to invest in
One British fintech hogs the headlines, but there are two top performers in the US. We explain where you should put your money
By David C. Stevenson Published